Kazia Therapeutics (NASDAQ: KZIA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-07 | ||||||
REV |
Q4 2021 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-07-08 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Kazia Therapeutics (NASDAQ: KZIA) through any online brokerage.
Other companies in Kazia Therapeutics’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Lumos Pharma (NASDAQ:LUMO), Aligos Therapeutics (NASDAQ:ALGS), NexImmune (NASDAQ:NEXI) and Genprex (NASDAQ:GNPX).
The latest price target for Kazia Therapeutics (NASDAQ: KZIA) was reported by Maxim Group on Thursday, October 14, 2021. The analyst firm set a price target for 18.00 expecting KZIA to rise to within 12 months (a possible 325.53% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Kazia Therapeutics (NASDAQ: KZIA) is $4.23 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Kazia Therapeutics.
Kazia Therapeutics’s Q2 earnings are confirmed for Sunday, August 7, 2022.
There is no upcoming split for Kazia Therapeutics.
Kazia Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.